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OBJECTIVES This study examines B-type natriuretic peptide (BNP) levels in patients with systolic versus
non-systolic dysfunction presenting with shortness of breath.
BACKGROUND Preserved systolic function is increasingly common in patients presenting with symptoms of
congestive heart failure (CHF) but is still difficult to diagnose.
METHODS The Breathing Not Properly Multinational Study was a seven-center, prospective study of
1,586 patients who presented with acute dyspnea and had BNP measured upon arrival. A
subset of 452 patients with a final adjudicated diagnosis of CHF who underwent echocar-
diography within 30 days of their visit to the emergency department (ED) were evaluated. An
ejection fraction of greater than 45% was defined as non-systolic CHF.
RESULTS Of the 452 patients with a final diagnosis of CHF, 165 (36.5%) had preserved left ventricular
function on echocardiography, whereas 287 (63.5%) had systolic dysfunction. Patients with
non-systolic heart failure (NS-CHF) had significantly lower BNP levels than those with
systolic heart failure (S-CHF) (413 pg/ml vs. 821 pg/ml, p  0.001). As the severity of heart
failure worsened by New York Heart Association class, the percentage of S-CHF increased,
whereas the percentage of NS-CHF decreased. When patients with NS-CHF were
compared with patients without CHF (n  770), a BNP value of 100 pg/ml had a sensitivity
of 86%, a negative predictive value of 96%, and an accuracy of 75% for detecting abnormal
diastolic dysfunction. Using Logistic regression to differentiate S-CHF from NS-CHF, BNP
entered first as the strongest predictor followed by oxygen saturation, history of myocardial
infarction, and heart rate.
CONCLUSIONS We conclude that NS-CHF is common in the setting of the ED and that differentiating
NS-CHF from S-CHF is difficult in this setting using traditional parameters. Whereas BNP
add modest discriminatory value in differentiating NS-CHF from S-CHF, its major role is
still the separation of patients with CHF from those without CHF. (J Am Coll Cardiol
2003;41:2010–7i) © 2003 by the American College of Cardiology Foundation
As many as 40% to 55% of patients with signs and
symptoms of congestive heart failure (CHF) have preserved
systolic function (1,2). Cardiac abnormalities in these pa-
tients are determined by a complex sequence of interrelated
events that may make diagnosis and the success of treatment
See page 2018
difficult to assess (3). While Doppler echocardiography has
been used to examine left ventricular (LV) filling dynamics
in these patients, the limitations of this technique suggest
the need for other objective measures in CHF patients with
preserved systolic function (4).
B-natriuretic peptide (BNP) is a cardiac neurohormone
secreted from the ventricles in response to ventricular
volume expansion and pressure overload (5,6). B-type na-
triuretic peptide levels are known to be elevated in patients
with symptomatic LV dysfunction and correlate to New
York Heart Association (NYHA) class as well as prognosis
(7–12). Recently, it has been shown that in patients with
preserved LV function, BNP levels may be reflective of
diastolic filling abnormalities on echocardiography (13,14).
This study examines BNP levels in patients presenting to
the emergency room with shortness of breath as part of the
multinational Breathing Not Properly study (15). To define
and differentiate characteristics of those with non-systolic
dysfunction from those patients with systolic dysfunction,
we utilized that subset of patients who had echocardio-
graphic determination of cardiac function within 30 days of
their initial visit.
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METHODS
Study population. The study was approved by the Insti-
tutional Review Boards of participating Breathing Not
Properly Multinational Study centers. A total of 1,586
patients from seven sites (five in the U.S., one in France, one
in Norway) were enrolled from April 1999 to December
2000. To be eligible for the study, the patient had to have
shortness of breath as their chief complaint. Patients under
age 18 and whose dyspnea was clearly not secondary to
CHF (e.g., trauma victims) were excluded. Patients with
acute myocardial infarction, severe renal failure, and unsta-
ble angina were excluded.
Once a patient was identified as having dyspnea, written
consent was obtained, and a blood sample was collected for
purposes of measuring the BNP concentration. Other data
were collected, including elements from the present and past
history, the physical examination, and reports of other blood
tests, interpretations of chest X-rays, or interpretations of
other diagnostic tests. Echocardiograms were strongly en-
couraged, either in the emergency department (ED), as an
outpatient, or in the hospital if the patient was admitted.
For each patient enrolled in the study, physicians as-
signed to the ED who were blinded to the results of BNP
measurements made an assessment of the probability of the
patient having CHF (0 to 100% clinical certainty) as the
cause of his or her symptoms at the time of ED disposition.
Confirmation of the diagnosis. To determine the patient’s
actual diagnosis, two cardiologists reviewed all medical
records pertaining to the patient and made independent
initial assessments of the final diagnosis: 1) CHF; 2) history
of CHF but acute dyspnea due to non-cardiac cause; or 3)
not CHF. The cardiologists were presented the components
and summary of the Framingham (two major or one major
and two minor criteria) CHF score and the National Health
and Nutrition and Examination Survey (score 3) CHF
score, calculated from the case report form. The cardiolo-
gists were blinded to the BNP results as well as the ED
physicians’ diagnosis. They did have access to the ED data
sheets and any additional information that became available
after the ED visit. This included the following: official
reading of the chest X-ray that was done in the ED by a
radiologist; past medical history obtained from a medical
chart that was not available at the time to the ED physi-
cians; the results of subsequent tests such as echocardiogra-
phy, radionuclide angiography, or left ventriculography
done at the time of cardiac catheterization; and the hospital
course for patients admitted to the hospital. For patients
with a diagnosis other than CHF, confirmation was at-
tempted using the following variables: normal chest X-ray
(lack of heart enlargement and pulmonary venous hyperten-
sion); X-ray signs of chronic obstructive lung disease,
pneumonia, or lung cancer; normal heart function by
echocardiography, nuclear medicine ejection fractions (EF),
or left ventriculography done at cardiac catheterization;
abnormal pulmonary function tests or follow-up in pulmo-
nary clinic; response to treatment in the ED or hospital with
nebulizers, steroids, or antibiotics; and no CHF admissions
over the next 30 days. In all cases of CHF, the two
cardiologists were asked to agree on the degree of severity of
CHF by ranking each patient as NYHA class I to IV.
Non-systolic versus systolic dysfunction. A subset of 452
patients with a final adjudicated diagnosis of CHF under-
went echocardiography within 30 days of their visit to the
ED. Patients with heart failure were defined as having
systolic heart failure (S-CHF) if the ejection was 45% or
less. Patients were defined as having non-systolic heart
failure (NS-CHF) if EF was 45%.
Measurement of BNP plasma levels. During initial eval-
uations, a blood sample was collected into tubes containing
potassium ethylenediaminetetraacetic acid. The BNP was
measured in triplicate using the Triage B-Type Natriuretic
Peptide test (Biosite Inc., San Diego, California). The
Triage BNP test is a fluorescence immunoassay for the
quantitative determination of BNP in whole blood and
plasma specimens. The precision, analytical sensitivity, and
stability characteristics of the system have been previously
described (16,17). Triplicate BNP values were determined
on site using the Triage BNP test with either whole blood
or plasma samples.
Statistics. For each of the different clinical and X-ray
findings identified by ED physicians, the percentage of
CHF cases with systolic dysfunction was computed. Group
comparisons of BNP values were made using Mann-
Whitney U tests. Other group comparisons were made
using chi-squared tests and t tests for independent samples.
Receiver operating characteristic (ROC) curves were used to
evaluate the utility of BNP for various diagnostic compar-
isons. Sensitivity, specificity, and accuracy are reported for
cut points of selected BNP concentrations. We also used a
stepwise multivariate logistic model combining clinical find-
ings and BNP values to differentiate between S-CHF and
NS-CHF. The BNP values were log-transformed in this
analysis to normalize the distribution.
RESULTS
The baseline characteristics for the overall study group of
1,586 patients are shown in Table 1. The mean age was 64
years. There were 883 (56%) males and 703 (44%) females.
Abbreviations and Acronyms
AUC  area under the curve
BNP  B-type natriuretic peptide
CHF  congestive heart failure
ED  emergency department
EF  ejection fraction
LV  left ventricular
NS-CHF  non-systolic congestive heart failure
NYHA  New York Heart Association
ROC  receiver operating characteristic
S-CHF  systolic congestive heart failure
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Ethnic makeup included 773 (49%) whites, 715 (45%)
blacks, and 98 (6%) classified as other races. Baseline
characteristics in patients with CHF who received echos
were similar to those who did not receive echos except they
were slightly younger, more often black, and had more
fatigue.
On examination by ED physicians, 7% of patients had an
S-3 gallop, 43% had rales in lower lung fields, 22% had
jugular venous distention, and 42% had lower extremity
edema. The final diagnosis (made retrospectively by two
cardiologists) was CHF in 744 patients (47%), a history of
CHF but dyspnea due to non-cardiac causes in 72 patients
(4.5%), and no CHF in 770 patients (49%). In 97% of
patients with CHF, the final diagnosis of CHF was con-
firmed by other tests (chest X-ray 79%, echocardiography
77%, radionuclide EF 15%, cardiac catheterization 19%,
and response to treatment 86%).
Of the 452 patients with a final diagnosis of CHF who
had echos within 30 days, 165 (36.5%) had preserved LV
function on echocardiography (NS-CHF), whereas 287 had
systolic dysfunction (S-CHF). The mean EF were 28 
0.6% and 59  0.6% in systolic and non-systolic dysfunc-
tion, respectively (p  0.001). Figure 1 presents box plots
showing median levels of BNP measured in the ED in
patients with dyspnea not due to heart failure, and those
with an adjudicated final diagnosis of heart failure, subdi-
vided by those with S-CHF and those with NS-CHF. The
median BNP level in the non-CHF groups was 34 pg/ml,
significantly lower than either those with S-CHF or NS-
CHF (p  0.001 in both cases). Patients with NS-CHF
had significantly lower BNP levels than those with S-CHF
(413 pg/ml vs. 821 pg/ml, p  0.001).
The relative proportions of systolic and non-systolic
dysfunction differed significantly as a function of severity of
CHF as agreed on by both cardiologists (p 0.001). Figure
2 shows a breakdown of each NYHA class in relation to
S-CHF and NS-CHF. As the severity of heart failure
worsened by NYHA classification, the proportion of
Table 1. Baseline Characteristics of Participants in the Breathing Not Properly Multinational
Study
All CHF
n % n %
Gender
Male 883 55.7 421 56.7
Female 703 44.3 321 43.3
Race
White 773 48.7 386 52.0
Black 715 45.1 314 42.3
Other 98 6.2 42 5.7
Age
Range 18–105 18–105
Mean 64 (SD  16.7) 70 (SD  14.53)
Presenting symptoms
Orthopnea 789 49.7 453 61.1
PND 668 42.1 383 51.6
Night cough 636 40.1 301 40.6
Fatigue 1,101 69.4 555 74.8
Weakness 1,067 67.3 537 72.4
History
CHF 527 33.2 421 56.7
MI 385 24.3 270 36.4
Angina 308 19.4 189 25.5
CABG 176 11.1 127 17.1
AFib 256 16.1 186 25.1
Hypertension 879 55.4 477 64.3
COPD 600 37.8 217 29.2
DM 367 23.1 130 32.0
AFib  atrial fibrillation; CABG  coronary artery bypass graft surgery; CHF  congestive heart failure; COPD  chronic
obstructive pulmonary disease; DM  diabetes mellitus; MI  myocardial infarction; PND  paroxysmal nocturnal dyspnea.
Figure 1. Box plots showing median levels of B-type natriuretic peptide
(BNP) measured in the emergency department in patients with dyspnea
not due to heart failure, in those with an adjudicated final diagnosis of
non-systolic left ventricular dysfunction, and in those with systolic left
ventricular dysfunction. CHF  congestive heart failure.
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S-CHF increased and the proportion of NS-CHF de-
creased.
Figure 3 presents box plots showing median levels of
BNP measured in men and women over 70 years of age with
dyspnea not due to heart failure, and those with an adjudi-
cated final diagnosis of heart failure, subdivided by those
with S-CHF and those with NS-CHF. The difference
between older men and woman with regard to BNP levels in
the non-CHF group was not statistically significant.
Among males, BNP was higher in both CHF groups than
control (p  0.001) but S-CHF and NS-CHF did not
differ. Among females, BNP was higher than control in
both types of CHF (p  0.001) and women with systolic
CHF had higher BNP levels than non-systolic failure
patients (p  0.03).
Table 2 shows univariate differences in patients with
S-CHF versus NS-CHF on presentation to the emergency
room. Patients with NS-CHF less often had a history of
heart failure (32% vs. 68%, p  0.015) or myocardial
infarction (29% vs. 71%, p  0.002) than those with
Figure 2. Number of patients in each New York Heart Association (NYHA) functional class with systolic versus non-systolic dysfunction.
Figure 3. Box plots showing median levels of B-type natriuretic peptide (BNP) measured in men and women over 70 years of age with dyspnea not due
to heart failure, and those with an adjudicated final diagnosis of heart failure, subdivided by those with systolic congestive heart failure (CHF) and those
with non-systolic CHF.
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S-CHF. On physical examination, patients with NS-CHF
had slower heart rates (88 vs. 93 beats/min, p  0.028),
higher systolic pressures (147 mm Hg vs. 137 mm Hg, p 
0.001), and lower mean oxygen saturations (91.8% vs.
94.2%, p  0.002). A third heart sound was present less
often in NS-CHF than S-CHF (26% vs. 74%, p  0.045).
The ability of BNP to detect abnormal heart function was
assessed with ROC curve analysis (Fig. 4). B-type natri-
uretic peptide was accurate in separating all CHF from
non-CHF patients (area under the curve [AUC]  0.90)
with 90% sensitivity at the established cutoff of 100 pg/ml.
The BNP levels were not very accurate in separating
S-CHF from NS-CHF (AUC  0.66, p  0.001). Al-
though a cut point of 100 pg/ml was 95% sensitive for
detecting S-CHF, there was significant overlap between the
two groups, with 86% of NS-CHF patients falling above
this cutoff.
Logistic regression was used in a multivariate approach
for differentiating systolic from non-systolic dysfunction in
patients diagnosed with heart failure (Table 3). The BNP
level, oxygen saturation, history of myocardial infarction,
and heart rate were the variables most closely associated
with separating the two entities.
DISCUSSION
As many as 40% to 55% of patients with the diagnosis of
heart failure have preserved systolic function (1,2). The
prevalence of CHF with preserved systolic function in-
creases with age, with an approximate incidence of 15% to
25% in people less than 60 years old, 35% to 40% between
60 and 70 years, and 50% in people over 70 years of age
(18,19).
Few data exist as to the proportion of patients who arrive
at the ED with dyspnea as a result of heart failure with
non-systolic LV dysfunction. The present study found that
slightly over one-third of patients presenting to the ED had
non-systolic dysfunction as determined by echocardiogra-
Table 2. Univariate Predictors of Systolic Versus Non-Systolic Dysfunction
Variable
% Systolic
p ValueWith Indicator
Without
Indicator
Gender (male) 69.4 55.8 0.003
Ethnicity — — NS
White 60.0 66.5 —
Black 65.6 61.5 —
History of CHF 67.7 56.3 0.015
History of MI 70.9 55.9 0.002
History of AFib/AFlutter 61.5 61.7 NS
History of hypertension 60.0 68.4 NS
History of diabetes 56.9 65.2 NS
History of COPD/asthma 61.9 61.7 NS
Orthopnea 65.2 57.9 NS
PND 66.8 51.8 NS
Elevated JVD 65.5 61.2 NS
Rales lower fields 63.3 63.4 NS
Rales upper fields 64.6 62.5 NS
S3 gallop 74.1 60.3 0.045
Murmurs 58.2 65.0 NS
Lower extremity edema 60.2 67.4 NS
Ischemic T-wave inversion 60.9 63.8 NS
Atrial fibrillation or flutter 57.3 64.7 NS
LBBB 79.6 61.5 0.013
Normal chest X-ray 61.3 63.9 NS
Heart size 65.9 60.0 NS
Cephalization of pulmonary vessels 65.0 62.7 NS
Alveolar edema 65.8 63.3 NS
Variable
Systolic
(mean  SEM)
Non-Systolic
(mean  SEM) p Value
Heart rate (beats/min) 93.4  1.5 88.1  1.9 0.028
Systolic pressure (mm Hg) 136.9  1.8 147.7  2.9  0.001
Diastolic pressure (mm Hg) 80.2  1.2 77.3  1.6 0.141
First oxygen saturation (%) 94.2  0.4 91.8  0.7 0.002
Weight (kg) 79.0  1.4 83.7  2.1 0.051
Creatinine (mg/dl) 1.3  0.0 1.2  0.0 0.077
Ejection fraction (%) 27.6  0.6 59.2  0.7  0.001
AFlutter  atrial flutter; JVD  jugular venous distension; LBBB  left bundle-branch block; NS  nonsignificant. Other
abbreviations as in Table 1.
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Figure 4. Receiver-operating characteristic curve for B-type natriuretic peptide (BNP) for differentiating between congestive heart failure (CHF) and non-CHF cases and between systolic versus non-systolic
dysfunction (non-CHF patients excluded). Tables show decision statistics at selected cut points. AUC  area under the curve.
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phy done within 30 days of their index visit. Correctly
diagnosing CHF in patients presenting with acute dyspnea
will not only allow one to accrue the benefits of improved
survival and increased well-being on medications such as
angiotensin-converting enzyme inhibitors and beta-blockers
(20), but also to avoid a misdiagnosis that could place the
patient at risk for both morbidity and mortality (21).
Using a rapid assay for BNP has allowed the prompt
differentiation of CHF from non-CHF causes of dyspnea,
regardless of the type of heart failure (8,15,16). Addition-
ally, BNP levels are highly prognostic in this setting.
Harrison et al. (22) followed 325 patients for six months
after an index visit to the ED for dyspnea and found that the
relative risk of six-month CHF death in patients with BNP
levels more than 230 pg/ml was 24.
It has been previously demonstrated that in the non-
emergency setting BNP is elevated in patients with NS-
CHF (13,14,20,23–25). Although BNP levels could not by
themselves differentiate between S-CHF and NS-CHF, a
low BNP level in the setting of normal systolic function by
echocardiography was able to rule out clinically significant
diastolic abnormalities seen on echo. On the other hand,
elevated BNP levels in patients with normal systolic func-
tion, especially in older patients with a history of CHF,
correlated to ventricular filling abnormalities on Doppler
studies (20,24).
In the present study, BNP was elevated in NS-CHF to a
median value of 413 pg/ml, higher than that seen in most
ambulatory patients with NS-CHF (13,14). Interestingly,
Lubien et al. (25) found BNP levels of 408 pg/ml in patients
with the restrictive filling pattern, the mitral Doppler
pattern most often associated with elevated LV end-
diastolic pressures. In patients with normal EF, a high BNP
level usually meant diastolic dysfunction. In the ED setting
this may be true as well. In the setting of dyspnea in which
LV function is normal, a BNP level 100 pg/ml gave a
negative predictive value of 96%.
With few exceptions, NS-CHF has not been shown to be
distinguishable from S-CHF solely on the basis of history,
physical examination, chest X-ray, and electrocardiogram
(1–3,26). Recently, Thomas et al. collected data on 225
patients hospitalized with CHF and found that differences
in clinical parameters could not predict systolic function in
these patients (26); the investigators suggested that special-
ized tests of ventricular function were needed. The present
study supports these data in that of all historical and
physical examination variables, only an absent history of
myocardial infarction or heart failure, an absent third heart
sound, and a high systolic blood pressure and lower heart
rate were more predictive of NS-CHF than S-CHF. B-type
natriuretic peptide levels are higher in patients with S-CHF
than in those with NS-CHF, possibly reflecting an associ-
ation with greater pathology in patients presenting with
S-CHF, as reflected by their higher NYHA classifications.
As the BNP level rises, the positive predictive value for
S-CHF also increases, so that a BNP level 400 pg/ml
offers a 72% likelihood that a patient will have S-CHF.
However, the marked overlap in BNP values clearly limits
its usefulness in separating the two groups in the clinical
setting.
The importance of differentiating patients with NS-CHF
from those with S-CHF lies in the underlying etiology and
the subsequent treatment of the individual patient. Abnor-
mal NS-CHF can be precipitated by ischemia, abnormally
high blood pressure, or atrial fibrillation, all of which would
receive different workups and treatment than used for
patients with S-CHF, who are more likely to be admitted to
the hospital and receive parenteral vasodilator and/or ino-
tropic therapy. The BNP levels clearly cannot substitute for
measurements of LV function and should not be considered
a surrogate for echocardiography.
In the future, BNP levels may provide a surrogate end
point for the evaluation of various treatments of heart
failure. Falling BNP levels with treatment is associated with
falling wedge pressures, a lower readmission rate to the
hospital, and a better prognosis (21,27). Thus, monitoring
BNP levels in future treatment protocols for NS-CHF may
provide valuable information regarding drug efficacy and
patient outcomes.
Study limitations. Echocardiographic recordings form the
basis for differentiating between S-CHF and NS-CHF in
the current study. Only 710 of the 1,586 patients (45%)
enrolled in the Breathing Not Properly multinational study
received echocardiograms within 30 days of their ED visit.
Numerous previous reports have validated the ability of
cardiac ultrasonography to detect abnormalities of contrac-
tile function and to quantitate LV volumes and EF (28,29).
All patients in this study so designated had clear-cut
evidence of LV systolic dysfunction. Although diastolic
dysfunction implies an abnormal relationship between LV
volume and pressure, echocardiography is capable of assess-
ing only parameters related to volume. As Doppler param-
Table 3. Logistic Regression in Attempt to Differentiate Systolic From Diastolic Heart Failure
Step
Predictor
Added
Direction in
Systolic CHF Exp. (B) p Value
1 BNP Higher 3.64 0.001
2 O2 saturation Higher 1.07 0.001
3 MI history Higher 2.11 0.002
4 Heart rate Higher 1.02 0.006
BNP  B-type natriuretic peptide; CHF  congestive heart failure; Exp. (B)  eB where B is the slope in logistic regression
equation; MI  myocardial infarction.
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eters such as transmitral and pulmonary venous flow veloc-
ities were not always recorded and provide only indirect
measurements of diastolic performance, they were not
evaluated in the context of the present study. We also used
a cutoff of 30 days for echocardiography, which meant that
the study might not have reflected the actual status in the
ED (30).
We conclude that BNP is a useful test to distinguish
patients with heart failure from those without heart failure.
This utility extends to the group with NS-CHF, in whom
the diagnosis is more difficult and often incorrectly excluded
when the presence of normal LV systolic function is known.
However, BNP cannot reliably distinguish S-CHF from
NS-CHF. Thus, a measurement of LV function is required
to make this distinction and guide therapy accordingly.
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